ClinicalTrials.gov
ClinicalTrials.gov Menu

An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02103426
Recruitment Status : Completed
First Posted : April 3, 2014
Last Update Posted : August 5, 2016
Sponsor:
Collaborator:
Vical
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of the study is to determine whether ASP0113 (a CMV deoxyribonucleic acid [DNA] vaccine) can be detected in plasma after intramuscular (IM) injections, and to determine whether CMV-seropositive healthy volunteers, CMV-seronegative healthy volunteers, CMV-seronegative dialysis patients mount an immune response to the CMV proteins produced by the vaccine after repeated ASP0113 IM injection.

Condition or disease Intervention/treatment Phase
Dialysis Healthy Subjects Cytomegalovirus Infection Drug: ASP0113 Drug: Placebo Phase 1

Detailed Description:
Part 1 is open-label with no randomization, and Part 2 is single-blind and randomized. The purpose of Part 1 is to obtain pilot pharmacokinetic data so as to optimize pharmacokinetic sample collection times in Part 2.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Prevention
Official Title: A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Study Start Date : December 2013
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part 1: ASP0113 CMV-seropositive healthy cohort
5 mg single dose IM injection
Drug: ASP0113
intramuscular injection

Experimental: Part 1: ASP0113 CMV-seronegative healthy cohort
5 mg single dose IM injection
Drug: ASP0113
intramuscular injection

Placebo Comparator: Part 1: Placebo CMV-seropositive healthy cohort
single dose IM injection
Drug: Placebo
intramuscular injection

Placebo Comparator: Part 1: Placebo CMV-seronegative healthy cohort
single dose IM injection
Drug: Placebo
intramuscular injection

Experimental: Part 2: ASP0113 CMV-seropositive healthy cohort
4 IM injections of ASP0113
Drug: ASP0113
intramuscular injection

Experimental: Part 2: ASP0113 CMV-seronegative healthy cohort
4 IM injections of ASP0113
Drug: ASP0113
intramuscular injection

Experimental: Part 2: ASP0113 CMV-seronegative dialysis cohort
4 IM injections of ASP0113
Drug: ASP0113
intramuscular injection

Placebo Comparator: Part 2: Placebo CMV-seropositive healthy cohort
4 placebo IM injections
Drug: Placebo
intramuscular injection

Placebo Comparator: Part 2: Placebo CMV-seronegative healthy cohort
4 placebo IM injections
Drug: Placebo
intramuscular injection

Placebo Comparator: Part 2: Placebo CMV-seronegative dialysis cohort
4 placebo IM injections
Drug: Placebo
intramuscular injection




Primary Outcome Measures :
  1. ASP0113 plasmids pharmacokinetics in plasma: AUC (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2) ]
    Area under the curve (AUC)

  2. ASP0113 plasmids pharmacokinetics in plasma: Cmax (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2 ]
    Maximum Concentration (Cmax)

  3. ASP0113 plasmids pharmacokinetics in plasma: Tmax (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2 ]
    Time to maximum concentration (Tmax)

  4. ASP0113 plasmids pharmacokinetics in plasma: Apparent clearance (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2 ]
  5. ASP0113 plasmids pharmacokinetics in plasma: apparent volume of distribution (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2 ]
  6. ASP0113 plasmids pharmacokinetics in plasma: half-life (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 and 28 for Part 1; Day 1, 2, 3, 4, 5, 6, 7 and weeks 5, 9 and 25 for Part 2 ]
  7. pp65 protein in white blood cells (WBCs) using pp65 antigenemia assay (Part 1 and Part 2) [ Time Frame: Day 1, 2, 3, 4, 5, 6, 7, 10, 14, 21 , 28 for Part 1; Day 1, 10, 14, weeks 5, 7, 9, 11, 25 and 27 for Part 2 ]
  8. Immunogenicity: Relative units/ml of anti-gB antibodies in serum as detected by enzyme-linked immunosorbent assay (ELISA) (Part 2) [ Time Frame: Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2) ]
  9. Immunogenicity: Number of pp65-specific Interferon (IFN)-gamma producing T-cells in isolated peripheral blood mononuclear cells (PBMCs) upon pp65 peptide stimulation as assayed by flow cytometry with intracellular cytokine staining (ICS) (Part 2) [ Time Frame: Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2) ]
  10. Immunogenicity: Amount of IFN-gamma produced by CMV peptide-stimulated T-cells in whole blood using the QuantiFERON T-cell CMV assay (Part 2) [ Time Frame: Day 1 and weeks 3, 5, 7, 9, 11, 25 and 27 (Part 2) ]
  11. Safety assessed by clinical labs, vital signs, and adverse events including local and systemic reactogenicity [ Time Frame: Up to Day 28 (Part 1), Up to 7 months (Part 2) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Main Inclusion for Healthy Subjects:

  • Body Mass Index (BMI) range of 18.5 - 35.0 kg/m2; weighs at least 50 kg at Screening.
  • Female subject must not be lactating and must not be breast feeding within 3 months before Screening or during the study period and for 28 days after final injection.
  • Female subject must not donate ova starting at Screening and throughout the study period and for 28 days after final injection.
  • Highly likely to comply with the protocol and complete the study.
  • Estimated creatinine clearance calculated using the Cockcroft-Gault equation of > 80 mL/min/1.73m2 (normal renal function).

Inclusion Criteria for Dialysis Patients:

  • BMI range of 18.5 - 40.0 kg/m2; weighs at least 50 kg at Screening.
  • Female subject must not be lactating and must not be breast feeding within 3 months before Screening or during the study period and for 30 days after final injection.
  • Female subject must not donate ova starting at Screening and throughout the study period and for 28 days after final study drug administration.
  • Must have adequate venous access.
  • Highly likely to comply with the protocol and complete the study.
  • Must currently be receiving hemodialysis treatment and for a period of at least 6 months prior to Screening.
  • CMV-seronegative at Screening.

Exclusion Criteria:

Main Exclusion Healthy Subjects

  • Female subject is pregnant at Screening.
  • Any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies).
  • Any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal (for healthy subjects only) and/or other major disease or malignancy (except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or cancer in situ of the cervix uteri that has been handled by local surgery).
  • History or evidence of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, psoriasis, psoriatic arthritis and inflammatory bowel disease.
  • Febrile illness or symptomatic, viral, bacterial (including upper respiratory infection) or fungal (non-cutaneous) infection within 1 week prior to day -14.
  • Any of the liver function tests (LFT) (aspartate amino-transferase [AST] or alanine aminotransferase [ALT] alkaline phosphatase (ALP), gamma-glutamyl transferase [GGT], total bilirubin [TBil]) outside of normal limits at Screening.
  • Mean pulse < 40 or > 90 beats per minute (bpm), mean systolic blood pressure (SBP) > 160 mmHg or mean diastolic blood pressure (DBP) > 90 mmHg taken in triplicate after the subject has been resting in a sitting position for at least 5 minutes at Screening.
  • Positive serology test for hepatitis B surface antigen (HBsAg) or hepatitis core immunoglobulin M (HBc [IgM]) antibody, anti-hepatitis A virus (HAV) IgM or anti-human immunodeficiency virus type 1 and type 2 (HIV-1 and HIV-2) at Screening.
  • Positive serology test for anti-hepatitis C virus (HCV) and a confirmatory positive reflex viral load test at Screening.
  • Current/ active CMV infection as evidenced by positive CMV Polymerase chain reaction (PCR) plasma results at Screening.
  • Any known or suspected hypersensitivity to ASP0113 or any components of the formulation used, including aminoglycosides as kanamycin is used during the manufacturing of the vaccine.
  • Use of any prescribed or non-prescribed drugs, alternative and complementary medications, except for vitamins, contraceptives, hormone replacement therapy and occasional acetaminophen (to a maximum of 2 g/day), within 14 days prior to first injection with ASP0113.
  • Vaccination with killed vaccines (including e.g., influenza and pneumococcal), or allergy treatment with antigen injections within 15 days prior to day -1.
  • Vaccination with live attenuated vaccines within 30 days prior to day -1.
  • Participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to day 1.
  • History of consuming more than 14 units of alcoholic beverages per week within 6 months prior to Screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1ounce of spirits/hard liquor).
  • Positive test for alcohol or drugs of abuse at Screening or day -1.
  • Significant blood loss, donation of 1 unit (450 mL) or more of blood or receipt of a transfusion of any blood, blood products or plasma within 90 days of day -1.
  • Contraindication to an intramuscular (IM) injection.
  • Employee of the Astellas Group or contract research organization (CRO) involved.

Exclusion Criteria for Dialysis Patients:

  • Female subject is pregnant at Screening.
  • Any clinically significant history of allergic conditions (including drug allergies, asthma, eczema, or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies).
  • Any history or evidence of any unstable, clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, metabolic, pulmonary, neurologic, dermatologic, psychiatric and/or other major disease or malignancy.
  • History of prior organ transplant, including a kidney, unless the transplant was unsuccessful and the subject is no longer receiving immunosuppressive therapy.
  • History or evidence of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, scleroderma, psoriasis, psoriatic arthritis and inflammatory bowel disease or other disease which may require use of an immunosuppressant medication during the trial.
  • Febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day-14.
  • Hemoglobin < 9 g/dL, TBil greater than the upper limit of normal (ULN), or an AST or ALT greater than 2 x the ULN at Screening. In such cases the assessment may be repeated once.
  • Mean pulse < 40 or > 100 bpm or mean SBP > 180 mmHg; mean DBP > 100 mmHg taken in triplicate after the subject has been resting in a sitting position for at least 5 minutes at Screening.
  • Positive serology test for HBsAg or HBc (IgM), anti HAV (IgM), anti-HIV-1 or anti-HIV-2 at Screening.
  • Positive serology test for anti-HCV and a confirmatory positive reflex viral load test at Screening.
  • Current/active CMV infection as evidenced by positive CMV PCR plasma results at Screening.
  • Known or suspected hypersensitivity to ASP0113 or any components of the formulation used, including aminoglycosides as kanamycin is used during the manufacturing of the vaccine.
  • Use of alternative and complementary medications except for vitamins, within 14 days prior to first injection with ASP0113.
  • Subject has had use of any immunosuppressive drugs, including but not limited to, systemic corticosteroids within 14 days or 5 half-lives of initial injection, whichever is longer. History of topical or inhaled corticosteroid use should be discussed with the Medical Monitor for evaluation.
  • Use of anticoagulants, including, but not limited to, vitamin K antagonists, heparin or its derivatives, low molecular weight heparin, factor X inhibitors or thrombin inhibitors within 5 half-lives of the first ASP0113 injection. Low dose anticoagulants used for prevention of deep vein thrombosis, prevention of fistula clotting, prevention of cardiovascular clotting, and heparin for use with dialysis procedure will be allowed after review and approval from the medical monitor.
  • Vaccination with killed vaccines (including e.g., influenza and pneumococcal), or allergy treatment with antigen injections between the date of screening and day-1.
  • Vaccination with live attenuated vaccines within 30 days prior to day-1.
  • Participated in any interventional clinical study or treatment with any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to day 1.
  • History of consuming more than 14 units of alcoholic beverages per week within 6 months prior to Screening or has a history of alcoholism or drug/chemical/substance abuse within past 2 years prior to Screening (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).
  • Positive test for alcohol or drugs of abuse (non-prescribed) at Screening or day -1.
  • Significant blood loss, donated 1 unit (450 mL) or more of blood or receipt of a transfusion of any blood, blood products or plasma within 90 days of day -14.
  • Contraindication to an IM injection.
  • Employee of the Astellas Group or CRO involved in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02103426


Locations
United States, California
Site US10009
Los Angeles, California, United States, 90017
United States, Florida
Site US10003
Orlando, Florida, United States, 32809
United States, Maryland
Site US10001
Baltimore, Maryland, United States, 21225
United States, Texas
Site US10004
Houston, Texas, United States, 77099
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Vical
Investigators
Study Director: Medical Director Astellas Pharma Global Development, Inc.

Responsible Party: Astellas Pharma Global Development, Inc.
ClinicalTrials.gov Identifier: NCT02103426     History of Changes
Other Study ID Numbers: 0113-CL-0004
First Posted: April 3, 2014    Key Record Dates
Last Update Posted: August 5, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
Cytomegalovirus
ASP0113
CMV-seropositive
Healthy subjects
CMV-seronegative
Dialysis

Additional relevant MeSH terms:
Cytomegalovirus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases